株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

マイクロバイオームの世界市場:2020年~2024年

Global Microbiomes Market 2020-2024

発行 TechNavio (Infiniti Research Ltd.) 商品コード 926713
出版日 ページ情報 英文 120 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.68円で換算しております。
マイクロバイオームの世界市場:2020年~2024年 Global Microbiomes Market 2020-2024
出版日: 2020年03月03日 ページ情報: 英文 120 Pages
概要

世界のマイクロバイオーム市場は、2020年から2024年の予測期間中に30%のCAGRで成長し、5億4,472万米ドルの規模に達する見込みです。同市場は、疾患の有病率の増加が成長要因の一つになっています。さらに、バイオセンサーと遺伝子回路の開発に対する関心の高まりが、市場成長を促進すると予測されています。

当レポートでは、世界のマイクロバイオーム市場について調査分析し、市場規模および成長率、市場動向、市場促進要因、課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提 供しています。

目次

エグゼクティブサマリー

  • 市場概況

市場情勢

  • 市場のエコシステム
  • バリューチェーン分析

市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模:2019年
  • 市場の見通し:2019-2024年の予測

ファイブフォース分析

  • ファイブフォースサマリー
  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • ライバルの脅威
  • 市況

市場セグメンテーション:アプリケーション別

  • 市場セグメンテーション
  • アプリケーション別比較:市場規模と予測2019-2024
  • 治療薬
  • 診断
  • 市場機会:アプリケーション別

顧客情勢

  • 概要

地域別情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模と予測2019-2024
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会:地域別

成長要因、課題、および動向

  • 市場成長要因
  • 数量的成長要因-需要主導型成長
  • 数量的成長要因-供給主導型成長
  • 数量的成長要因-外部要因
  • 数量的成長要因-隣接市場での需要シフト
  • 価格上昇要因-インフレ
  • 価格上昇要因-低価格ユニットから高価格ユニットへの移行
  • 市場の課題
  • 市場動向

ベンダー情勢

  • 概要
  • ベンダー情勢
  • 情勢の革新

ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • 4D pharma Plc
  • ENTEROME SA
  • Evelo Biosciences Inc.
  • Ferring International Center SA
  • Osel Inc.
  • Second Genome Inc.
  • Seres Therapeutics Inc.
  • Synlogic Inc.
  • Synthetic Biologics Inc.
  • Vedanta Biosciences Inc.

付録

  • 調査範囲
  • 米ドルの通貨換算レート
  • 調査方法
  • 略語のリスト
目次
Product Code: IRTNTR41199

Technavio has been monitoring the global microbiomes market 2020-2024 and it is poised to grow by USD 544.72 mn during 2020-2024, progressing at a CAGR of 30% during the forecast period. Our reports on global microbiomes market 2020-2024 provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of diseases. In addition, growing focus on developing biosensors and genetic circuits is anticipated to boost the growth of the global microbiomes market 2020-2024 as well.

Market Segmentation

Technavio's ‘ global microbiomes market 2020-2024’ is segmented as below:

Application:

  • Therapeutics
  • Diagnostics

Geographic segmentation

  • Asia
  • Europe
  • North America
  • ROW

Key Trends for global microbiomes market 2020-2024 growth

This study identifies growing focus on developing biosensors and genetic circuits as the prime reasons driving the global microbiomes market 2020-2024 growth during the next few years.

Prominent vendors in global microbiomes market 2020-2024

We provide a detailed analysis of around 25 vendors operating in the global microbiomes market 2020-2024, including some of the vendors such as 4D pharma Plc, ENTEROME SA, Evelo Biosciences Inc., Ferring International Center SA, Osel Inc., Second Genome Inc., Seres Therapeutics Inc., Synlogic Inc., Synthetic Biologics Inc. and Vedanta Biosciences Inc. .

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Application

  • Market segments
  • Comparison by Application placement
  • Therapeutics - Market size and forecast 2019-2024
  • Diagnostics - Market size and forecast 2019-2024
  • Market opportunity by Application

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Volume driver - Demand shift in adjacent markets
  • Price driver - Inflation
  • Price driver - Shift from lower to higher-priced units
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • 4D Pharma Plc
  • ENTEROME SA
  • Evelo Biosciences, Inc.
  • Ferring International Center SA
  • Osel Inc.
  • Second Genome Inc.
  • Seres Therapeutics Inc.
  • Synlogic Inc.
  • Synthetic Biologics Inc.
  • Vedanta Biosciences Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

List of Exhibits:

  • 1.Key Finding 1
  • 2.Key Finding 2
  • 3.Key Finding 3
  • 4.Key Finding 4
  • 5.Key Finding 5
  • 6.Key Finding 6
  • 7.Key Finding 7
  • 8.Market in focus
  • 9.Parent market
  • 10.Market characteristics
  • 11.Product / Service portfolio of key vendors included in the market definition
  • 12.Market segments
  • 13.Global - Market size and forecast 2019 - 2024 ($ million)
  • 14.Global market: Year-over-year growth 2019 - 2024 (%)
  • 15.Five forces analysis 2019 & 2024
  • 16.Bargaining power of buyers
  • 17.Bargaining power of suppliers
  • 18.Threat of new entrants
  • 19.Threat of substitutes
  • 20.Threat of rivalry
  • 21.Market condition - Five forces 2019
  • 22.Application placement - Market share 2019-2024 (%)
  • 23.Comparison by Application placement
  • 24.Therapeutics - Market size and forecast 2019-2024 ($ million)
  • 25.Therapeutics - Year-over-year growth 2019-2024 (%)
  • 26.Diagnostics - Market size and forecast 2019-2024 ($ million)
  • 27.Diagnostics - Year-over-year growth 2019-2024 (%)
  • 28. Market opportunity by Application
  • 29.Customer landscape
  • 30.Market share by geography 2019-2024 (%)
  • 31.Geographic comparison
  • 32.North America - Market size and forecast 2019-2024 ($ million)
  • 33.North America - Year-over-year growth 2019-2024 (%)
  • 34.Europe - Market size and forecast 2019-2024 ($ million)
  • 35.Europe - Year-over-year growth 2019-2024 (%)
  • 36.Asia - Market size and forecast 2019-2024 ($ million)
  • 37.Asia - Year-over-year growth 2019-2024 (%)
  • 38.ROW - Market size and forecast 2019-2024 ($ million)
  • 39.ROW - Year-over-year growth 2019-2024 (%)
  • 40.Key leading countries
  • 41.Market opportunity by geography ($ million)
  • 42.Impact of drivers
  • 43.Impact of challenges
  • 44.Landscape disruption
  • 45.Industry risks
  • 46.Vendors covered
  • 47.Market positioning of vendors
  • 48.4D pharma Plc - Overview (1/3)
  • 49.4D pharma Plc - Overview (2/3)
  • 50.4D pharma Plc - Overview (3/3)
  • 51.4D pharma Plc - Business segments
  • 52.4D pharma Plc - Key offerings
  • 53.4D pharma Plc - Key customers
  • 54.4D pharma Plc - Segment focus
  • 55.ENTEROME SA - Overview (1/3)
  • 56.ENTEROME SA - Overview (2/3)
  • 57.ENTEROME SA - Overview (3/3)
  • 58.ENTEROME SA - Product and service
  • 59.ENTEROME SA - Key offerings
  • 60.ENTEROME SA - Key customers
  • 61.ENTEROME SA - Segment focus
  • 62.Evelo Biosciences Inc. - Overview (1/3)
  • 63.Evelo Biosciences Inc. - Overview (2/3)
  • 64.Evelo Biosciences Inc. - Overview (3/3)
  • 65.Evelo Biosciences Inc. - Business segments
  • 66.Evelo Biosciences Inc. - Key offerings
  • 67.Evelo Biosciences Inc. - Key customers
  • 68.Evelo Biosciences Inc. - Segment focus
  • 69.Ferring International Center SA - Overview (1/3)
  • 70.Ferring International Center SA - Overview (2/3)
  • 71.Ferring International Center SA - Overview (3/3)
  • 72.Ferring International Center SA - Product and service
  • 73.Ferring International Center SA - Key offerings
  • 74.Ferring International Center SA - Key customers
  • 75.Ferring International Center SA - Segment focus
  • 76.Osel Inc. - Overview (1/3)
  • 77.Osel Inc. - Overview (2/3)
  • 78.Osel Inc. - Overview (3/3)
  • 79.Osel Inc. - Product and service
  • 80.Osel Inc. - Key offerings
  • 81.Osel Inc. - Key customers
  • 82.Osel Inc. - Segment focus
  • 83.Second Genome Inc. - Overview (1/3)
  • 84.Second Genome Inc. - Overview (2/3)
  • 85.Second Genome Inc. - Overview (3/3)
  • 86.Second Genome Inc. - Product and service
  • 87.Second Genome Inc. - Key offerings
  • 88.Second Genome Inc. - Key customers
  • 89.Second Genome Inc. - Segment focus
  • 90.Seres Therapeutics Inc. - Overview (1/3)
  • 91.Seres Therapeutics Inc. - Overview (2/3)
  • 92.Seres Therapeutics Inc. - Overview (3/3)
  • 93.Seres Therapeutics Inc. - Business segments
  • 94.Seres Therapeutics Inc. - Key offerings
  • 95.Seres Therapeutics Inc. - Key customers
  • 96.Seres Therapeutics Inc. - Segment focus
  • 97.Synlogic Inc. - Overview (1/3)
  • 98.Synlogic Inc. - Overview (2/3)
  • 99.Synlogic Inc. - Overview (3/3)
  • 100.Synlogic Inc. - Business segments
  • 101.Synlogic Inc. - Key offerings
  • 102.Synlogic Inc. - Key customers
  • 103.Synlogic Inc. - Segment focus
  • 104.Synthetic Biologics Inc. - Overview (1/3)
  • 105.Synthetic Biologics Inc. - Overview (2/3)
  • 106.Synthetic Biologics Inc. - Overview (3/3)
  • 107.Synthetic Biologics Inc. - Product and service
  • 108.Synthetic Biologics Inc. - Key offerings
  • 109.Synthetic Biologics Inc. - Key customers
  • 110.Synthetic Biologics Inc. - Segment focus
  • 111.Vedanta Biosciences Inc. - Overview (1/3)
  • 112.Vedanta Biosciences Inc. - Overview (2/3)
  • 113.Vedanta Biosciences Inc. - Overview (3/3)
  • 114.Vedanta Biosciences Inc. - Product and service
  • 115.Vedanta Biosciences Inc. - Key offerings
  • 116.Vedanta Biosciences Inc. - Key customers
  • 117.Vedanta Biosciences Inc. - Segment focus
  • 118.Currency conversion rates for US$
  • 119.Research Methodology
  • 120.Validation techniques employed for market sizing
  • 121.Information sources
  • 122.List of abbreviations